5 results on '"Dewkoemar Ramsoekh"'
Search Results
2. Systematic review: non-endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome
- Author
-
Elsa L. S. A. van Liere, Nanne K. H. de Boer, Evelien Dekker, Monique E. van Leerdam, Tim G. J. de Meij, Dewkoemar Ramsoekh, Gastroenterology and hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Pediatrics, and Amsterdam Reproduction & Development (AR&D)
- Subjects
Adenoma ,Hepatology ,Occult Blood ,Gastroenterology ,Biomarkers, Tumor ,Humans ,Pharmacology (medical) ,Colonoscopy ,Colorectal Neoplasms ,Colorectal Neoplasms, Hereditary Nonpolyposis ,neoplasms ,Early Detection of Cancer ,digestive system diseases - Abstract
BACKGROUND: Individuals with Lynch syndrome are at high risk for colorectal cancer (CRC). Regular colonoscopies have proven to decrease CRC incidence and mortality. However, colonoscopy is burdensome and interval CRCs still occur. Hence, an accurate, less-invasive screening method that guides the timing of colonoscopy would be of important value.AIM: To outline the performance of non-endoscopic screening modalities for Lynch-associated CRC and adenomas.METHODS: Systematic literature search in MEDLINE and EMBASE to identify studies investigating imaging techniques and biomarkers for detection of CRC and adenomas in Lynch syndrome. The QUADAS-2 tool was used for the quality assessment of included studies.RESULTS: Seven of 1332 screened articles fulfilled the inclusion criteria. Two studies evaluated either CT colonography or MR colonography; both techniques were unable to detect CRC and (advanced) adenomas CONCLUSIONS: Imaging techniques are unsuitable for colon surveillance in Lynch syndrome, whereas biomarkers are understudied. Having outlined biomarker research in Lynch-associated and sporadic CRC/adenomas, we believe that these non-invasive markers may hold potential (whether or not combined) for this population. As they could be of great value, (pre-)clinical studies in this field should be prioritised.
- Published
- 2022
3. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome
- Author
-
Eelco J. R. de Graaf, Celine H. Leenen, Anja Wagner, Monique E. van Leerdam, Pieter J. Westenend, Ernst J. Kuipers, Dewkoemar Ramsoekh, W. W. Vrijland, Hendrikus J. Dubbink, Ewout W. Steyerberg, L. M. M. Wolters, Winand N.M. Dinjens, Ans M.W. van den Ouweland, and Margot G. van Lier
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Colorectal cancer ,Microsatellite instability ,Odds ratio ,medicine.disease ,Logistic regression ,Gastroenterology ,digestive system diseases ,Lynch syndrome ,Pathology and Forensic Medicine ,Surgery ,Internal medicine ,Predictive value of tests ,medicine ,business ,Prospective cohort study ,Genetic testing - Abstract
Although early detection of Lynch syndrome (LS) is important, a considerable proportion of patients with LS remains unrecognized. We aimed to study the yield of LS detection by routine molecular analyses in colorectal cancer (CRC) patients until 70 years of age. We prospectively included consecutive CRC patients ≤70 years. Tumour specimens were analysed for microsatellite instability (MSI), immunohistochemical mismatch-repair protein expression and MLH1-promoter methylation. Tumours were classified as either: (a) likely caused by LS; (b) sporadic microsatellite-unstable (MSI-H); or (c) microsatellite-stable (MSS). Predictors of LS were determined by multivariable logistic regression. A total of 1117 CRC patients (57% males, median age 61 years) were included. Fifty patients (4.5%, 95% CI 3.4-5.9) were likely to have LS, and 71 had a sporadic MSI-H tumour (6.4%, 95% CI 5.1-8.0). Thirty-five patients likely to have LS (70%) were aged > 50 years. A molecular profile compatible with LS was detected in 10% (15/144) of patients aged ≤50, in 4% (15/377) of those aged 51-60 and in 3% (20/596) of patients > 61 years. Compared to MSS cases, patients likely to have LS were significantly younger (OR 3.9, 95% CI 1.7-8.7) and more often had right-sided CRCs (OR 14, 95% CI 6.0-34). In conclusion, molecular screening for LS in CRC patients ≤70 years leads to identification of a molecular profile compatible with LS in 4.5% of patients, with most of them not fulfilling the age criterion (≤50 years) routinely used for LS assessment. Routine use of MSI testing may be considered in CRC patients up to the age of 70 years, with a central role for the pathologist in the selection of patients.
- Published
- 2012
4. Review article: detection and management of hereditary non-polyposis colorectal cancer (Lynch syndrome)
- Author
-
Anja Wagner, Dewkoemar Ramsoekh, E. J. Kuipers, and M E van Leerdam
- Subjects
Oncology ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Hepatology ,business.industry ,Colorectal cancer ,Genetic counseling ,Gastroenterology ,nutritional and metabolic diseases ,Cancer ,Microsatellite instability ,medicine.disease ,digestive system diseases ,Lynch syndrome ,Internal medicine ,Mutation (genetic algorithm) ,medicine ,Pharmacology (medical) ,Age of onset ,Family history ,business ,neoplasms - Abstract
Background The most common hereditary colorectal cancer syndrome is hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome. Diagnosis of this syndrome is difficult, because of lack of specific diagnostic fatures. Aim To discuss the diagnostic criteria and laboratory work up for HNPCC. Furthermore, survelillance programs for HNPCC and treatment of HNPCC associated colorectal cancer are discussed. Results Current diagnostic criteria, including the Amsterdam II and Bethesda criteria, are suboptimal for the detection of HNPCC. Molecular screening by microsatellite instability (MSI) and immunohistochemistry (IHC) is useful in the diagnosis of HNPCC. Both techniques have a higher sensitivity compared to the Amsterdam II and Bethesda criteria. A combination of both MSI and IHC provides the most optimal selection for mutation analysis. After identification of a mutation in an affected individual, genetic counselling and presymptomatic mutation analysis should be offered to relatives. Furthermore, colonoscopic surveillance should be performed in proven mutation carriers. Conclusions Identification of HNPCC is a clinical challenge involving many clinicians. Identification of persons at risk can be achieved by a combination of a detailed family history, testing with molecular and mutation analysis.
- Published
- 2007
5. The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP
- Author
-
Carli M. J. Tops, Dennis Dooijes, Ernst J. Kuipers, Ewout W. Steyerberg, Dewkoemar Ramsoekh, Anja Wagner, M E van Leerdam, Gastroenterology & Hepatology, Clinical Genetics, Public Health, and Internal Medicine
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Colorectal cancer ,Genetic counseling ,DNA Mutational Analysis ,Pedigree chart ,DNA Glycosylases ,Familial adenomatous polyposis ,Cohort Studies ,SDG 3 - Good Health and Well-being ,Risk Factors ,MUTYH ,Internal medicine ,Genetics ,medicine ,Humans ,Genetic Testing ,Genetics (clinical) ,Genetic testing ,medicine.diagnostic_test ,business.industry ,Cancer ,Syndrome ,medicine.disease ,Colorectal Neoplasms, Hereditary Nonpolyposis ,Adenomatous Polyposis Coli ,Mutation (genetic algorithm) ,Female ,Colorectal Neoplasms ,business - Abstract
This study evaluated the use of genetic testing and time trends in hereditary non-polyposis colorectal cancer (HNPCC), (attenuated) familial adenomatous polyposis [(A)FAP] and human MutY homolog (MUTYH) associated polyposis (MAP) families. Eighty-seven families, who were diagnosed with disease-causing mutations between 1995 and 2006, were included in this study. The families consisted of 1547 individuals at risk. Data of these individuals were collected from medical records and family pedigrees. There was considerable interest in genetic testing with test rates of 41% in HNPCC families, 42% in (A)FAP families and 53% in MAP families. The use of genetic testing was associated with age and parenthood. Despite the interest in genetic testing, many risk carriers do not apply for testing. Moreover, time trend analysis showed a decline in test rate in HNPCC families. Studies evaluating the reasons for not testing are needed. Furthermore, a better implementation of genetic testing in clinical practice is desirable.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.